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Should population program of Pap smear screening tests for cervical 
cancer be continued in Poland?
Urszula Wojciechowska
Population screening programs should be efficient and cost-effective. Cervical cancer screening program was imple-
mented in Poland in 2006 and so far it did not achieve the main goal of the screening, which is to reduce the mortality 
rate of cervical cancer in the entire female population. 
The main reason of this are: poor organization that causes low quality of the program at every stage of its activity, 
low participation of women in screening and lack of reliable program monitoring.
The organization of screening program in Poland significantly deviates from the international recommendations 
what led to lack of cost-effectiveness of the program. It is time to make a bold decision and end the program until a 
modern strategy is developed that would account for the latest global recommendations including e.g. vaccinations 
against HPV virus and HPV test as a screening test.
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Population screening programs for early detection of ce-
rvical cancer were implemented in many European countries 
over 20 years ago (in Scandinavian countries, they have been 
continued for over 50 years); this enabled determination of 
principles that allow for constructing the programs in such 
a way to make them efficient and cost-effective.
A population screening program should fulfill some 
requirements, including the following [1]:
1. It concerns an important health-related and social pro-
blem;
2. The natural history of the disease is well known and 
understood;
3. The disease can be cured at the early stage (there should 
be a pre-clinical condition);
4. The treatment results are much better when the therapy 
is initiated at an early stage;
5. There is an acceptable screening test;
6. The test has applicably high sensitivity and specificity;
7. There are methods to cure the detected disease in an 
effective manner;
8. The screening test is performed in repeated time incre-
ments, until the risk of disease exists;
9. The benefits of the program exceed the risk;
10. Population costs of test are not higher than treatment 
costs.
The screening program implemented in Poland in 2006 
fulfills the first five criteria.
The remaining five requirements are not fulfilled, ma-
inly due to organizational issues, which results in lack of 
population efficiency of the screening program in Poland.
Failure to fulfill the other conditions and an attempt to 
evaluate the causes requires a more detailed discussion.
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Item 6. The test has applicably high sensitivity 
and specificity.
As a screening test for early detection of cervical cancer, 
conventional Pap smear test (Papanicolaou test) was ap-
plied. The sensitivity of this test is on average 50% (30–87%), 
i.e. in 5 out of 10 women, cytological abnormalities will not 
be detected [2]. Smear evaluation, according to the interna-
tional recommendations, is performed using Bethesda sys-
tem, which is the basis for therapeutic decisions. Inaccurate 
result may lead to implementation of premature therapeutic 
steps or failure to implement them when necessary, which 
can influence the overall effectiveness of the program and 
potential health issues resulting from participation in the 
program.
According to NFZ (National Health Fund) data, in the 
initial years of the screening program, 15–20% of smears 
were unsuitable for evaluation. In 2012, 17% of 764,656 Pap 
smears were obtained improperly (Tab. I). The sensitivity of 
the test in Poland was not estimated. Based on the NFZ data, 
it may be assumed that its sensitivity is significantly lower 
than 50%. Lack of publications about this issue means that 
the problem was not recognized at all.
Item 7. There are methods to cure the detected 
disease in an effective manner
Effectiveness of treatment can be assessed using 5-year 
survival rates. Based on the most recent results from Con-
cord-3 project 5-year, survival rates for cervical cancer pa-
tients have increased over the last 15 years in the countries 
with the highest rate values (65–70%: Norway, Finland, Swe-
den, the Netherlands, Italy) by only 2–3 percentage points, 
which indicates that there is no progress in treatment of 
this cancer even in the countries where organized scre-
ening for cervical cancer is implemented. Survival rate for 
cervical cancer patients in Poland also increased in Poland 
in 2000–2014 by 3 percentage points (from 52% to 55%), 
but the rate value varies from the European values by 10–18 
percentage points (Fig. 1). 8-year duration of the screening 
program included into the Concord-3 analysis did not result 
in a significant improvement in patient survival in Poland 
[3]. There were no changes indicating that cervical cancer 
was detected at an earlier stage during this period, which 
is the main objective of the secondary prevention. This is 
one of many arguments showing lack of effectiveness of 
the screening program in Poland.
Table I. Number of procedures reimbursed by the NFZ; Pap smears performed within the scope of the population program between 2012 and 2014
Year 2012 2013 2014 2015
Total number of tests 764,656 694,762 720,662 685,225
Number of tests that could be assessed 631,694 581,553 691,991 681,555
Incorrect smears 132,962 113,209 28,671 3670
% of incorrectly performed smears 17% 16% 4% 1%
Normal result 740,687 673,028 696,510 662,815
Pathological epithelial cells were found 19,721 18,359 20,202 18,740
Number of tests 
where abnormal 
squamous epithelial 
cells were detected
In total 18,930 17,598 17,983 17,983
ASC-US 9690 8136 8043 8043
HSIL (ASC-H) 1481 1445 1574 1574
HSIL - CIN2 CIN3/CIS 2123 1931 1957 1957
Squamous carcinoma 153 159 143 143
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Figure 1. Five-year survival rates for cervical cancer in selected European countries
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Item 8. The screening test is performed in 
repeated time increments until the risk of 
disease exists
One of the main tasks for the screening organizers is to 
encourage women to have regular Pap smear tests perfor-
med. The population effect is noticeable if 70% of female 
population included in screening (aged 25–59) regularly 
i.e. every 3 years takes the test within the scope of the pro-
gram. The program organizers should invite new cohorts 
of women thus increasing the percentage of the tested 
population.
Over the whole period of the screening program dura-
tion in Poland only 18–22% of female population from the 
target group underwent the Pap smear within the scope of 
the organized program (Fig. 2, Tab. II). There is no information 
whether these are new cohorts of women reaching the age 
covered by the program or the same health education-prone 
women who regularly undergo all preventive tests. There 
is also no information available whether the total number 
of women participating in the program is increasing and 
what are the reasons for the limited participation of women 
in the screening tests. In Finland evaluation of decrease in 
attendance and its causes led to improvement in attendance 
by 10 p.p. (from 70% to more than 80%) [4].
Such a low participation of women in the screening 
program does not allow for obtaining the assumed objective 
— decrease of cervical cancer mortality. In 2016 elimination 
of inviting women for tests which, according to international 
recommendations, is one of the most important activities 
ensuring high attendance, led to decrease in attendance by 
3 p.p. in the following year (Fig. 2). 
As possible reasons for low participation of women in 
the organized program, the organizers of the screening pro-
gram indicate performing Pap smears outside the program 
(within the scope of AOS (Outpatient Specialist Care) and 
not recording the results in a Screening Program Monitoring 
System (SIMP). Number of Pap smears performed outside 
the organized program increases attendance to about 40% 
(Tab. III).
It is, however, not certain whether the Pap smears re-
ported by AOS as screening tests are not in fact diagnostic 
smears. It is not known whether the women screened by 
AOS fulfill all program requirements (age interval).
Even if we assume that the actual screening attendance 
is close to 40%, then why there is no population effect of the 
program implemented almost 10 years ago?
Simulation prognosis performed by the KRN (Polish Na-
tional Cancer Registry) in 2006 i.e. a year before the screening 
program was implemented shows two scenarios for the co-
urse of trends for the cervical cancer mortality: pessimistic 
(continuation of the trend in case of no intervention) and 
optimistic (decrease of the mortality trend up to the annual 
Table II. Number of collected smears and cervical cancer screening 
attendance in Poland in 2007–2013 (source: NFZ)
Year Target  
population
Screened 
population
Attendance 
(in %)
2007 3,227,918 686,036 21.3
2008 3,252,888 793,411 24.4
2009 3,274,036 876,538 26.8
2010 3,289,805 796,446 24.2
2011 3,293,187 804,555 24.4
2012 3,293,976 765,301 23.2
2013 3,290,725 697,407 21.2
Figure 2. Map of cervical cancer screening attendance in Poland in 2015–2017
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Table III. Number of Pap smears performed within the organized program and AOS (source: NFZ)
Year Women registered in SIMP Smears taken by midwives within AOS SIMP+AOS
Number % Number % Number %
2010 796,366 24.2 No data No data No data No data
2011 804,494 24.4 No data No data No data No data
2012 765,040 23.2 633,564 12.3 1,137,764 35.5
2013 696,920 21.2 753,948 22.0 1,419,468 43.1
2014 724,598 22.1 736,662 21.4 1,428,344 43.5
Figure 3. Simulated prognosis of trend for cervical cancer mortality in 
Poland (source: KRN)
Figure 4. Cervical cancer mortality in Poland in 1965–2015
average of 5%, which was observed after the implementation 
of the screening program in Finland) (Fig. 3). A well-organized 
screening program in Finland (attendance of over 80% of 
target female population) led to rapid decrease in mortality 
due to cervical cancer in the initial years of the program and 
to annual average decrease in mortality rates by about 5% 
in the following years. Covering the target population to 
the greatest possible extent seems to be the key to success.
Upon analysis of time trends for cervical cancer mortality 
in Poland, we observe the pessimistic scenario (no interven-
tion). There is no change in the overall mortality trend; the 
rate of decrease in the mortality rates remains at the level 
of about 2% annually (Fig. 3).
More detailed analyses have shown that the screening 
program brought measurable effects in a group of women 
aged 25–59 but no population-wide effect was observed 
and additionally decrease in incidence and mortality trends 
in women older than 60 who were not screened decelerated 
after implementation of the program [5] (Fig. 4).
Item 9. The benefits of the program exceed the risk
Procedures used in screening tests for detecting cervical 
cancer may have adverse effect for the physical and mental 
health of participating women. The following harms are 
mentioned: pain, bleeding after the examination, vaginal di-
scharge, fear of unfavorable result, premature birth in young 
women after aggressive procedures within the cervix [6]. 
In Poland there are no data on the balance of harms and 
benefits of the program which makes it impossible to modify 
the recommendations in such a way to minimize the losses 
related to the program.
Item 10. Population-wide costs of screening are 
not higher than treatment costs
Publications on the costs of the cervical cancer screening 
program are ambiguous. Estimation of treatment costs for 
2017 based on NFZ data covering analysis of medical proce-
dures performed in women diagnosed with cervical cancer 
in 2005–2010 and treated until the end of 2015 suggests 
that average cost of cervical cancer treatment is about 25 
thousand PLN [7].
A different publication using the same source shows 
that the annual cost of treating cervical cancer regardless 
of the diagnosis date is 1564 PLN [8] (Tab. IV).
Number of women with cervical cancer treated in 2012 
seems overestimated as compared to KRN data. The obse-
rved 10-year prevalence estimated by KRN is 17,500 women. 
Number of cervical cancer patients treated is comparable 
to the sum of incidences over a period of 11 years (about 
3000 per year) if none of the women would die. Maybe this 
is why the yearly cost of cervical cancer treatment in this 
publication seems underestimated.
According to NFZ data, the total cost of screening pro-
gram (diagnostics and administration) in 2012 would be 
close to 61 million PLN (39 million PLN NFZ and 22 million 
PLN MZ — the Ministry of Health) (Tab. V). If we estima-
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Table V. Costs of the screening program for detection of cervical cancer (source: NFZ, the Ministry of Health [9])
YEAR Number of 
examined 
women
Costs
 NFZ
Number of 
examined women
Number of squamous cell 
carcinomas
MZ costs Cost of detecting 
1 cervical cancer 
case in PLNat the step of extent diagnostics
2007 675,633 28,542,144 3309 231    
2008 767,505 32,750,887 3280 243    
2009 827,290 43,196,229 4094 212    
2010 763,880 39,712,388 3099 145 12, 505,639 360,124
2011 750,310 39,617,909 3047 165    
2012 729,890 38,990,940 3031 153 21,793,882 397,286
2013 666,197 35,463,714 3032 159    
2014 700,205 27,91,677 3806 148    
Table IV. Costs of diagnostics and treatment of cervical lesions according to NFZ in 2012
Type of intervention/diagnosis Number of cases (unique records in 
NFZ databases — prevalence)
Costs (PLN) Cost per 1 patient (PLN)
Pap smears 2,053,624 53,621,062 26
CIN1 10,521 6,616,375 629
CIN2 5812 5,071,155 873
CIN3 6487 7,611,062 1173
CIN (undetermined) 36,575 12,352,034 338
Cervical cancer 33,482 52,377,006 1564
te the cost of diagnosing 1 advanced cervical cancer in 
the screening program, we get an extremely high sum of 
397,286 PLN, which would cover a yearly cost of treatment 
for 19 patients. However the point of the screening program 
is to detect premalignant conditions, hence it would be 
good to estimate the cost of preventing the disease. In 
2012 within the screening program abnormal squamous 
epithelial cells being potentially the initial stage of cancer 
were found in 19 thousand patients. Only some of them 
would result in invasive cancer in a perspective of 10–15 
years (estimated time of disease development). However, 
even the pessimistic scenario assuming that in 2012 the 
program prevented 19 thousand future cervical cancer ca-
ses allows for estimating the cost of an annual treatment for 
these patients at a level of about 47 million (19 thousand × 
1564 PLN) i.e. 14 million less than an annual cost of cervical 
cancer screening program.
Hence it seems that the discussed program is completely 
cost-ineffective. The main reason for this is lack of reliable 
program monitoring and its poor organization. According to 
international recommendations, organization of a screening 
program should minimize the negative effects of the pro-
gram and maximize the program benefits. Benefits may be 
obtained only when the program quality is optimal at every 
stage of its activity. One of the main recommendations is 
regular participation of at least 70% of population covered 
by screening, which can be obtained only in a program 
with invitations and regular monitoring of the program for 
assessment of Pap smear quality. Until now it is not known 
why Polish women are reluctant to have a free Pap smear.
In 2017 the Ministry of Health gave up inviting women 
to participate in the screening program, which soon resulted 
in decreased percentage of Pap smear attendance to about 
18%. At the same time organization of the program was 
assigned to the local authorities, who appointed the entities 
to implement the program by way of competition; however 
the chosen entities often lacked knowledge and experience 
in implementing the screening program. As an example, the 
competitive process in Warmińsko-Mazurskie Voivodship 
resulted in hiring the Fundacja of Gazeta Olsztyńska. Ano-
ther example of bad program organization is assigning the 
quality control of basic and extent diagnostics procedures in 
Poland to an individual medical practice, thus surrendering 
the key activity of the screening project to one person not 
subject to any control. The above-mentioned principles of 
organization significantly deviate from the international 
recommendations and are among many reasons for lack 
of population effectiveness of the screening program in 
our country, both until now and in future, if the program 
is continued.
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Monitoring of quality efficiency and cost-efficiency of 
the screening program for detecting cervical cancer in Po-
land is also poor. With the system for screening program 
monitoring SIMP, NFZ database, database of the Polish Na-
tional Cancer Registry (KRN) no reliable analysis was made 
to assess justifiability of program continuation, indicating 
the strengths and weaknesses of the program and providing 
grounds to build further strategy to prevent cervical cancer 
in Poland.
Such analyses were not performed mainly because it is 
impossible to combine and exchange data from the abo-
ve-mentioned sources. With lack of randomization in the 
screening program, the assessment of its efficiency should 
utilize data from the cancer registry. However, information 
about detection of cancer collected in SIMP is not available 
for KRN, hence the registry cannot perform the above tasks.
The discussed question must be answered: should 
a  badly organized ineffective cost-inefficient population 
program of screening Pap smear tests in cervical cancer be 
continued in Poland? Can we afford further high costs of 
the program that has no chances of reaching the assumed 
objectives?
We should make a bold decision and end the program 
until a modern strategy is developed that would account 
for the latest global recommendations including e.g. vac-
cinations against HPV virus and HPV test as screening test.
It is time to reduce losses, develop a new action plan 
eliminating the errors that were made until now, to set new 
realistic goals matching financial and organizational capabi-
lity of Poland (e.g. to put education and primary prevention 
first). We should implement monitoring of actions from the 
initiation of the new strategy implementation and flexible 
attitude towards the organizational changes in the program 
that would allow for its correction to quickly obtain the 
assumed objectives.
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